1 Introduction to Research & Analysis Reports
1.1 Bladder Cancer Targeted Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Bladder Cancer Targeted Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Bladder Cancer Targeted Drug Overall Market Size
2.1 Global Bladder Cancer Targeted Drug Market Size: 2022 VS 2029
2.2 Global Bladder Cancer Targeted Drug Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Bladder Cancer Targeted Drug Players in Global Market
3.2 Top Global Bladder Cancer Targeted Drug Companies Ranked by Revenue
3.3 Global Bladder Cancer Targeted Drug Revenue by Companies
3.4 Top 3 and Top 5 Bladder Cancer Targeted Drug Companies in Global Market, by Revenue in 2022
3.5 Global Companies Bladder Cancer Targeted Drug Product Type
3.6 Tier 1, Tier 2 and Tier 3 Bladder Cancer Targeted Drug Players in Global Market
3.6.1 List of Global Tier 1 Bladder Cancer Targeted Drug Companies
3.6.2 List of Global Tier 2 and Tier 3 Bladder Cancer Targeted Drug Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Bladder Cancer Targeted Drug Market Size Markets, 2022 & 2029
4.1.2 Atezolizumab (Tecentriq)
4.1.3 Avelumab (Bavencio)
4.1.4 Erdafitinib (Balversa)
4.1.5 Other
4.2 By Type – Global Bladder Cancer Targeted Drug Revenue & Forecasts
4.2.1 By Type – Global Bladder Cancer Targeted Drug Revenue, 2018-2023
4.2.2 By Type – Global Bladder Cancer Targeted Drug Revenue, 2024-2029
4.2.3 By Type – Global Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Bladder Cancer Targeted Drug Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Retail Pharmacy
5.1.4 Other
5.2 By Application – Global Bladder Cancer Targeted Drug Revenue & Forecasts
5.2.1 By Application – Global Bladder Cancer Targeted Drug Revenue, 2018-2023
5.2.2 By Application – Global Bladder Cancer Targeted Drug Revenue, 2024-2029
5.2.3 By Application – Global Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Bladder Cancer Targeted Drug Market Size, 2022 & 2029
6.2 By Region – Global Bladder Cancer Targeted Drug Revenue & Forecasts
6.2.1 By Region – Global Bladder Cancer Targeted Drug Revenue, 2018-2023
6.2.2 By Region – Global Bladder Cancer Targeted Drug Revenue, 2024-2029
6.2.3 By Region – Global Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Bladder Cancer Targeted Drug Revenue, 2018-2029
6.3.2 US Bladder Cancer Targeted Drug Market Size, 2018-2029
6.3.3 Canada Bladder Cancer Targeted Drug Market Size, 2018-2029
6.3.4 Mexico Bladder Cancer Targeted Drug Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Bladder Cancer Targeted Drug Revenue, 2018-2029
6.4.2 Germany Bladder Cancer Targeted Drug Market Size, 2018-2029
6.4.3 France Bladder Cancer Targeted Drug Market Size, 2018-2029
6.4.4 U.K. Bladder Cancer Targeted Drug Market Size, 2018-2029
6.4.5 Italy Bladder Cancer Targeted Drug Market Size, 2018-2029
6.4.6 Russia Bladder Cancer Targeted Drug Market Size, 2018-2029
6.4.7 Nordic Countries Bladder Cancer Targeted Drug Market Size, 2018-2029
6.4.8 Benelux Bladder Cancer Targeted Drug Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Bladder Cancer Targeted Drug Revenue, 2018-2029
6.5.2 China Bladder Cancer Targeted Drug Market Size, 2018-2029
6.5.3 Japan Bladder Cancer Targeted Drug Market Size, 2018-2029
6.5.4 South Korea Bladder Cancer Targeted Drug Market Size, 2018-2029
6.5.5 Southeast Asia Bladder Cancer Targeted Drug Market Size, 2018-2029
6.5.6 India Bladder Cancer Targeted Drug Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Bladder Cancer Targeted Drug Revenue, 2018-2029
6.6.2 Brazil Bladder Cancer Targeted Drug Market Size, 2018-2029
6.6.3 Argentina Bladder Cancer Targeted Drug Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Bladder Cancer Targeted Drug Revenue, 2018-2029
6.7.2 Turkey Bladder Cancer Targeted Drug Market Size, 2018-2029
6.7.3 Israel Bladder Cancer Targeted Drug Market Size, 2018-2029
6.7.4 Saudi Arabia Bladder Cancer Targeted Drug Market Size, 2018-2029
6.7.5 UAE Bladder Cancer Targeted Drug Market Size, 2018-2029
7 Bladder Cancer Targeted Drug Companies Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Bladder Cancer Targeted Drug Major Product Offerings
7.1.4 Pfizer Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 Merck KGaA
7.2.1 Merck KGaA Company Summary
7.2.2 Merck KGaA Business Overview
7.2.3 Merck KGaA Bladder Cancer Targeted Drug Major Product Offerings
7.2.4 Merck KGaA Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.2.5 Merck KGaA Key News & Latest Developments
7.3 Roche
7.3.1 Roche Company Summary
7.3.2 Roche Business Overview
7.3.3 Roche Bladder Cancer Targeted Drug Major Product Offerings
7.3.4 Roche Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.3.5 Roche Key News & Latest Developments
7.4 Astellas
7.4.1 Astellas Company Summary
7.4.2 Astellas Business Overview
7.4.3 Astellas Bladder Cancer Targeted Drug Major Product Offerings
7.4.4 Astellas Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.4.5 Astellas Key News & Latest Developments
7.5 Janssen Biotech
7.5.1 Janssen Biotech Company Summary
7.5.2 Janssen Biotech Business Overview
7.5.3 Janssen Biotech Bladder Cancer Targeted Drug Major Product Offerings
7.5.4 Janssen Biotech Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.5.5 Janssen Biotech Key News & Latest Developments
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Company Summary
7.6.2 Bristol-Myers Squibb Business Overview
7.6.3 Bristol-Myers Squibb Bladder Cancer Targeted Drug Major Product Offerings
7.6.4 Bristol-Myers Squibb Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.6.5 Bristol-Myers Squibb Key News & Latest Developments
7.7 Merck & Co.
7.7.1 Merck & Co. Company Summary
7.7.2 Merck & Co. Business Overview
7.7.3 Merck & Co. Bladder Cancer Targeted Drug Major Product Offerings
7.7.4 Merck & Co. Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.7.5 Merck & Co. Key News & Latest Developments
7.8 Gilead Sciences
7.8.1 Gilead Sciences Company Summary
7.8.2 Gilead Sciences Business Overview
7.8.3 Gilead Sciences Bladder Cancer Targeted Drug Major Product Offerings
7.8.4 Gilead Sciences Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.8.5 Gilead Sciences Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Bladder Cancer Targeted Drug Market Opportunities & Trends in Global Market
Table 2. Bladder Cancer Targeted Drug Market Drivers in Global Market
Table 3. Bladder Cancer Targeted Drug Market Restraints in Global Market
Table 4. Key Players of Bladder Cancer Targeted Drug in Global Market
Table 5. Top Bladder Cancer Targeted Drug Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Bladder Cancer Targeted Drug Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Bladder Cancer Targeted Drug Revenue Share by Companies, 2018-2023
Table 8. Global Companies Bladder Cancer Targeted Drug Product Type
Table 9. List of Global Tier 1 Bladder Cancer Targeted Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Bladder Cancer Targeted Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Bladder Cancer Targeted Drug Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Bladder Cancer Targeted Drug Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Bladder Cancer Targeted Drug Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Bladder Cancer Targeted Drug Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Bladder Cancer Targeted Drug Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Bladder Cancer Targeted Drug Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2024-2029
Table 30. Pfizer Company Summary
Table 31. Pfizer Bladder Cancer Targeted Drug Product Offerings
Table 32. Pfizer Bladder Cancer Targeted Drug Revenue (US$, Mn) & (2018-2023)
Table 33. Pfizer Key News & Latest Developments
Table 34. Merck KGaA Company Summary
Table 35. Merck KGaA Bladder Cancer Targeted Drug Product Offerings
Table 36. Merck KGaA Bladder Cancer Targeted Drug Revenue (US$, Mn) & (2018-2023)
Table 37. Merck KGaA Key News & Latest Developments
Table 38. Roche Company Summary
Table 39. Roche Bladder Cancer Targeted Drug Product Offerings
Table 40. Roche Bladder Cancer Targeted Drug Revenue (US$, Mn) & (2018-2023)
Table 41. Roche Key News & Latest Developments
Table 42. Astellas Company Summary
Table 43. Astellas Bladder Cancer Targeted Drug Product Offerings
Table 44. Astellas Bladder Cancer Targeted Drug Revenue (US$, Mn) & (2018-2023)
Table 45. Astellas Key News & Latest Developments
Table 46. Janssen Biotech Company Summary
Table 47. Janssen Biotech Bladder Cancer Targeted Drug Product Offerings
Table 48. Janssen Biotech Bladder Cancer Targeted Drug Revenue (US$, Mn) & (2018-2023)
Table 49. Janssen Biotech Key News & Latest Developments
Table 50. Bristol-Myers Squibb Company Summary
Table 51. Bristol-Myers Squibb Bladder Cancer Targeted Drug Product Offerings
Table 52. Bristol-Myers Squibb Bladder Cancer Targeted Drug Revenue (US$, Mn) & (2018-2023)
Table 53. Bristol-Myers Squibb Key News & Latest Developments
Table 54. Merck & Co. Company Summary
Table 55. Merck & Co. Bladder Cancer Targeted Drug Product Offerings
Table 56. Merck & Co. Bladder Cancer Targeted Drug Revenue (US$, Mn) & (2018-2023)
Table 57. Merck & Co. Key News & Latest Developments
Table 58. Gilead Sciences Company Summary
Table 59. Gilead Sciences Bladder Cancer Targeted Drug Product Offerings
Table 60. Gilead Sciences Bladder Cancer Targeted Drug Revenue (US$, Mn) & (2018-2023)
Table 61. Gilead Sciences Key News & Latest Developments
List of Figures
Figure 1. Bladder Cancer Targeted Drug Segment by Type in 2022
Figure 2. Bladder Cancer Targeted Drug Segment by Application in 2022
Figure 3. Global Bladder Cancer Targeted Drug Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Bladder Cancer Targeted Drug Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Bladder Cancer Targeted Drug Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Bladder Cancer Targeted Drug Revenue in 2022
Figure 8. By Type - Global Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
Figure 9. By Application - Global Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
Figure 10. By Type - Global Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
Figure 12. By Application - Global Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
Figure 14. By Region - Global Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
Figure 15. By Country - North America Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
Figure 16. US Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
Figure 20. Germany Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 21. France Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
Figure 28. China Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 32. India Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
Figure 34. Brazil Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
Figure 37. Turkey Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 41. Pfizer Bladder Cancer Targeted Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Merck KGaA Bladder Cancer Targeted Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Roche Bladder Cancer Targeted Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Astellas Bladder Cancer Targeted Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Janssen Biotech Bladder Cancer Targeted Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Bristol-Myers Squibb Bladder Cancer Targeted Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Merck & Co. Bladder Cancer Targeted Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Gilead Sciences Bladder Cancer Targeted Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)

※参考情報 膀胱がんは、泌尿器系の悪性腫瘍の一つであり、特に高齢者に多く見られる疾患です。近年、がんの治療法は多様化しており、膀胱がんにおいても標的薬（ターゲット治療）が注目されています。標的薬は、がん細胞の特定の分子や経路を標的とし、高い選択性を持つため、副作用が少ないとされる治療法です。 膀胱がん標的薬の定義は、膀胱がん細胞に特異的に作用することで、その増殖を抑制したり、死滅を引き起こしたりする薬剤を指します。これらの薬剤は、膀胱がん細胞に特有の遺伝子変異や、特定の細胞表面の受容体に対して作用することにより、正常細胞に対して影響を与えにくく、より効率的な治療が期待されます。 膀胱がん標的薬の特徴は、その高い選択性にあります。従来の化学療法と比較して、健全な細胞へのダメージが少なく、患者の生活の質を向上させる可能性があります。また、標的薬は、がんの進行状況や遺伝子プロファイリングによって、個別に患者に合わせた治療が行える点も大きな特徴です。例えば、ある患者に対しては特定の受容体をターゲットにした薬剤が効果的であるのに対して、別の患者には異なる標的薬が必要となることがあります。 膀胱がんに使用される標的薬には幾つかの種類があります。代表的なものには、プラチナ製剤や、免疫療法薬であるチェックポイント阻害薬が含まれます。プラチナ製剤は、DNAの複製を阻害することによって、がん細胞の増殖を抑えます。また、チェックポイント阻害薬は、がん細胞が免疫系から逃れる所を妨げることで、体自身の免疫力を高め、がん細胞を攻撃することを助けます。最近の研究では、これらの薬剤を組み合わせた治療法が新たな治療戦略として注目されています。 さらに、膀胱がん治療における標的薬の用途は多岐にわたります。例えば、手術後の adjuvant (補助) 療法として用いることができたり、進行した膀胱がんに対する治療に用いられたりします。また、特に再発性の膀胱がんに対しても効果が期待され、治療選択肢を広げる役割を果たしています。このように、標的薬は膀胱がん治療の重要な要素として位置付けられています。 関連技術としては、がん細胞の分子解析技術やバイオマーカー研究が挙げられます。これらの技術により、患者の腫瘍に特有の遺伝子変異を同定し、最も効果的な標的薬を選択するための重要な情報を得ることができます。また、これにより、治療の効果予測や副作用管理がより適切に行われる可能性が高まります。 近年の研究動向としては、膀胱がんの分子基盤に関する理解が深まっており、それに基づいた新たな標的薬の開発が進められています。例えば、ERBB2やFGFR3などの遺伝子異常が存在する膀胱がんに対して特異的に作用する薬剤の研究が盛んです。これにより、今後ますます個別化医療が進展し、多くの患者に対してより高い効果が期待される治療法が提供されることでしょう。 膀胱がん標的薬は、従来の治療法に比べて新たな選択肢を提供し、多くの患者の生活の質を向上させる可能性を秘めています。今後も、膀胱がんに関する研究と治療法の進展により、より多くの患者に効果的な治療が行えることが期待されています。そのためには、継続的な研究と臨床試験が不可欠であり、科学者や医療従事者が一丸となって取り組む必要があると考えられます。 膀胱がんという重い疾患に対して、標的薬は希望の光となる存在です。今後の研究や技術の進展によって、より多くの患者に利益をもたらし、新たな治療法が確立されることが期待されます。医療の現場においても、標的薬の正しい理解と活用が求められるでしょう。ぜひ、今後の進展に注目していきたいと思います。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer